Welcome to our dedicated page for Soleno Therapeutics SEC filings (Ticker: SLNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Soleno Therapeutics filings document the regulatory, financial, governance, and capital-structure disclosures of a Nasdaq-listed biopharmaceutical company commercializing VYKAT XR for hyperphagia associated with Prader-Willi syndrome. Recent Form 8-K reports cover operating results and launch updates, regulatory and marketing-authorization matters for diazoxide choline, material agreements, share-repurchase arrangements, and the company's common stock registration on Nasdaq.
The filing record also includes board-approved bylaw amendments, officer appointments and compensation arrangements, exhibits to earnings releases, and material-event disclosures related to strategic transactions. These documents formalize the company's public reporting around product commercialization, corporate governance, executive compensation, and risk-related business developments.
Soleno Therapeutics insider Patricia C. Hirano, Senior Vice President of Regulatory Affairs, executed a planned transaction under Rule 10b5-1 on June 24, 2025. The transaction involved:
- Exercise of employee stock options for 266 shares at $44.25 per share
- Immediate sale of the acquired 266 shares at $84.25 per share
- Net gain of $40 per share on the transaction
Following the transactions, Hirano holds 17,036 shares directly, some in the form of restricted stock units (RSUs). Notable adjustments include a 10,000-share reduction from an internal holdings review. The transactions were executed according to a trading plan established on September 13, 2024, demonstrating compliance with insider trading regulations.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) – Form 144 insider selling notice
The filing discloses that an affiliate—identified in the past-three-month sales table as Patricia Hirano—plans to sell 266 common shares through Morgan Stanley Smith Barney on or about 24 June 2025. At the reference price used in the form, the transaction is valued at $22,410.50. The shares were obtained the same day via a stock-option exercise; therefore no new shares will be issued and the sale represents just 0.0005 % of the 50.39 million shares outstanding.
The more material information is the history of insider sales included in the filing. In the preceding three months Ms. Hirano executed 14 separate sales totaling ≈160,097 shares for ≈$11 million in gross proceeds. The proposed 266-share sale appears to be a continuation of that pattern. No reference is made to a pre-arranged Rule 10b5-1 trading plan, although the form provides the option to disclose such a plan.
Investor takeaways:
- The imminent sale is immaterial in isolation, but the cumulative selling pace may raise questions about insider sentiment.
- No new dilution: the transaction merely transfers already-issued shares from an insider to the public market.
- No operational, earnings or strategic information is provided; the filing is limited to insider-trading disclosure.